argenx SE (ARGX)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
€842.00
Buy
€865.00
€3.80 (+0.45%)
Prices updated at 29 Sep 2026, 16:36 CEST
| Prices minimum 15 mins delay
Prices in EUR
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company’s lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myas ...
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
| €861.40 - €843.80 | |
| €925.00 - €568.40 | |
| - | |
| 52,839.01m | |
| 36.61 | |
| - | |
| 59,602 | |
| 7.14 | |
| 86,951.34 | |
| -0.07 | |
| 61.88m | |
| NL0010832176 | |
| 19.57 | |
| - |
Please note that past performance is not a reliable indicator of future returns. Pre-sale Illustration.